$ATYR
aTyr Pharma Inc

2021 Q3 Form 10-Q Financial Statement

#000156459021056699 Filed on November 12, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2020 Q3 2020 Q1
Revenue $0.00 $148.0K $8.065M
YoY Change -100.0% -19.57%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.590M $2.040M $2.590M
YoY Change 26.96% 8.51% 2.37%
% of Gross Profit
Research & Development $5.138M $4.616M $3.620M
YoY Change 11.31% 21.51% 8.06%
% of Gross Profit
Depreciation & Amortization $123.0K $130.0K $157.0K
YoY Change -5.38% -18.75% -5.99%
% of Gross Profit
Operating Expenses $7.728M $6.660M $6.206M
YoY Change 16.04% 17.21% 5.6%
Operating Profit -$7.728M -$6.512M
YoY Change 18.67% 18.44%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $59.00K -$88.00K -$110.0K
YoY Change -167.05% -40.14% -57.69%
Pretax Income -$7.669M -$6.600M $1.750M
YoY Change 16.2% 16.81% -128.5%
Income Tax
% Of Pretax Income
Net Earnings -$7.669M -$6.599M $1.752M
YoY Change 16.21% 16.9% -128.55%
Net Earnings / Revenue -4458.78% 21.72%
Basic Earnings Per Share -$0.42 $0.25
Diluted Earnings Per Share -$422.2K -$683.9K $0.25
COMMON SHARES
Basic Shares Outstanding 18.16M 6.882M
Diluted Shares Outstanding 18.16M 6.885M

Balance Sheet

Concept 2021 Q3 2020 Q3 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $116.4M $36.10M $49.80M
YoY Change 222.31% -5.16% 15.81%
Cash & Equivalents $59.74M $18.15M $39.45M
Short-Term Investments $56.61M $18.00M $10.40M
Other Short-Term Assets $5.089M $1.800M $500.0K
YoY Change 182.72% 63.64% -54.55%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $121.6M $38.20M $50.40M
YoY Change 218.25% -2.41% 12.75%
LONG-TERM ASSETS
Property, Plant & Equipment $2.186M $3.300M $3.900M
YoY Change -33.76% 138.1% -22.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $158.0K $100.0K $100.0K
YoY Change 58.0% -54.75% -50.0%
Total Long-Term Assets $2.344M $3.400M $4.000M
YoY Change -31.06% -26.1% -23.08%
TOTAL ASSETS
Total Short-Term Assets $121.6M $38.20M $50.40M
Total Long-Term Assets $2.344M $3.400M $4.000M
Total Assets $123.9M $41.60M $54.40M
YoY Change 197.88% -4.9% 9.02%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $900.0K $1.400M $700.0K
YoY Change -35.71% 5.74% -12.5%
Accrued Expenses $4.920M $3.600M $2.700M
YoY Change 36.67% 127.99% 42.11%
Deferred Revenue $143.0K
YoY Change -77.3%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $3.100M $6.866M
YoY Change -60.48% -11.97%
Total Short-Term Liabilities $5.820M $8.000M $10.45M
YoY Change -27.25% -32.36% -6.74%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Other Long-Term Liabilities $657.0K $1.600M $2.000M
YoY Change -58.94% -33.33% -28.57%
Total Long-Term Liabilities $657.0K $1.600M $2.000M
YoY Change -58.94% -41.65% -78.26%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.820M $8.000M $10.45M
Total Long-Term Liabilities $657.0K $1.600M $2.000M
Total Liabilities $6.304M $9.500M $12.30M
YoY Change -33.64% -34.8% -39.71%
SHAREHOLDERS EQUITY
Retained Earnings -$363.7M
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $117.6M $32.20M $42.10M
YoY Change
Total Liabilities & Shareholders Equity $123.9M $41.60M $54.45M
YoY Change 197.88% -4.9% 9.11%

Cashflow Statement

Concept 2021 Q3 2020 Q3 2020 Q1
OPERATING ACTIVITIES
Net Income -$7.669M -$6.599M $1.752M
YoY Change 16.21% 16.9% -128.55%
Depreciation, Depletion And Amortization $123.0K $130.0K $157.0K
YoY Change -5.38% -18.75% -5.99%
Cash From Operating Activities -$11.47M -$5.550M $2.058M
YoY Change 106.67% 30.28% -134.17%
INVESTING ACTIVITIES
Capital Expenditures -$61.00K -$10.00K $166.0K
YoY Change 510.0% -66.67% 1560.0%
Acquisitions
YoY Change
Other Investing Activities -$14.79M $1.750M $11.57M
YoY Change -945.03% -75.8% -445.37%
Cash From Investing Activities -$14.85M $1.740M $11.41M
YoY Change -953.39% -75.87% -439.97%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 83.87M 330.0K 16.78M
YoY Change 25314.85% -375.0% -2810.66%
NET CHANGE
Cash From Operating Activities -11.47M -5.550M 2.058M
Cash From Investing Activities -14.85M 1.740M 11.41M
Cash From Financing Activities 83.87M 330.0K 16.78M
Net Change In Cash 57.55M -3.480M 30.24M
YoY Change -1753.74% -222.97% -402.52%
FREE CASH FLOW
Cash From Operating Activities -$11.47M -$5.550M $2.058M
Capital Expenditures -$61.00K -$10.00K $166.0K
Free Cash Flow -$11.41M -$5.540M $1.892M
YoY Change 105.94% 30.97% -131.36%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y8M12D
CY2021Q3 life Stock Issued During Period Value At The Market Offerings Net Of Offering Costs
StockIssuedDuringPeriodValueAtTheMarketOfferingsNetOfOfferingCosts
3184000
CY2021Q3 life Issuance Of Common Stock From Underwritten Follow On Offering Net Of Offering Costs
IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCosts
80627000
CY2021Q3 us-gaap Profit Loss
ProfitLoss
-7669000
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
117439000
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
21026000
CY2020Q1 life Issuance Of Common Stock From Underwritten Follow On Offering Net Of Offering Costs
IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCosts
18779000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
423000
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-13000
CY2020Q1 us-gaap Profit Loss
ProfitLoss
1752000
CY2020Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
41967000
CY2020Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
6000
CY2020Q2 life Stock Issued During Period Value At The Market Offerings Net Of Offering Costs
StockIssuedDuringPeriodValueAtTheMarketOfferingsNetOfOfferingCosts
25000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
378000
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
9000
CY2020Q2 us-gaap Profit Loss
ProfitLoss
-6447000
CY2020Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
35938000
CY2020Q3 life Stock Issued During Period Value At The Market Offerings Net Of Offering Costs
StockIssuedDuringPeriodValueAtTheMarketOfferingsNetOfOfferingCosts
2334000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
324000
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
2000
CY2020Q3 us-gaap Profit Loss
ProfitLoss
-6600000
CY2020Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
31998000
us-gaap Profit Loss
ProfitLoss
-25216000
us-gaap Profit Loss
ProfitLoss
-11295000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
367000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
441000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1200000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1125000
us-gaap Accretion Expense
AccretionExpense
324000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-143000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-55000
life Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
617000
life Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
579000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-10000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-1910000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
145000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3244000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1146000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-133000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
862000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-155000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-633000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-555000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-24989000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9900000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
174000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
197000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
68811000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
20168000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
26767000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
24050000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
12000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-42218000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
3697000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
59000
life Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
5000
life Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
6000
life Proceeds From Issuance Of Common Stock Through At Market Offering Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockThroughAtMarketOfferingNetOfOfferingCosts
14070000
life Proceeds From Issuance Of Common Stock Through At Market Offering Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockThroughAtMarketOfferingNetOfOfferingCosts
2359000
life Proceeds From Issuance Of Common Stock Through Registered Direct Offering Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockThroughRegisteredDirectOfferingNetOfOfferingCosts
15236000
life Proceeds From Issuance Of Common Stock Through Underwritten Follow On Offering Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockThroughUnderwrittenFollowOnOfferingNetOfOfferingCosts
80627000
life Proceeds From Issuance Of Common Stock Through Underwritten Follow On Offering Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockThroughUnderwrittenFollowOnOfferingNetOfOfferingCosts
18779000
us-gaap Repayments Of Debt
RepaymentsOfDebt
6000000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
109997000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15144000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
42790000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
8941000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
16952000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
9210000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
59742000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
18151000
us-gaap Net Income Loss
NetIncomeLoss
-25200000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-363700000
CY2021Q3 life Cash And Cash Equivalents And Available For Sale Investments
CashAndCashEquivalentsAndAvailableForSaleInvestments
116400000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-align:justify;margin-bottom:6pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:3.75%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our condensed consolidated financial statements are prepared in accordance with GAAP. The preparation of our condensed consolidated financial statements requires us to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure for these items in our condensed consolidated financial statements and accompanying notes. The most significant estimates in our condensed consolidated financial statements relate to clinical trial and research and development expenses. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ materially from these estimates and assumptions.</p>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1294576
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
598266
CY2021Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
56631000
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
3000
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
22000
CY2021Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
56612000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
14730000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
7000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
14737000
CY2021Q3 us-gaap Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1
19
CY2021Q3 us-gaap Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear
30
CY2020Q1 life Upfront Payment Received
UpfrontPaymentReceived
8000000.0
CY2021Q1 life Milestone Payment Received
MilestonePaymentReceived
2000000.0
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
262000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1062000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
404000
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
122000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1606000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
949000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
657000
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
200000
CY2020Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
200000
us-gaap Operating Lease Cost
OperatingLeaseCost
700000
us-gaap Operating Lease Cost
OperatingLeaseCost
700000
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.096
CY2021Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
1788997
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
576534
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
23.33
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
749539
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.48
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
10173
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.86
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
44364
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
22.87
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1271536
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
324000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1200000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1125000

Files In Submission

Name View Source Status
0001564590-21-056699-index-headers.html Edgar Link pending
0001564590-21-056699-index.html Edgar Link pending
0001564590-21-056699.txt Edgar Link pending
0001564590-21-056699-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
life-10q_20210930.htm Edgar Link pending
life-10q_20210930_htm.xml Edgar Link completed
life-20210930.xsd Edgar Link pending
life-20210930_cal.xml Edgar Link unprocessable
life-20210930_def.xml Edgar Link unprocessable
life-20210930_lab.xml Edgar Link unprocessable
life-20210930_pre.xml Edgar Link unprocessable
life-ex311_7.htm Edgar Link pending
life-ex312_8.htm Edgar Link pending
life-ex321_6.htm Edgar Link pending
life-ex322_9.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending